Last edition
News about "BioCryst Strengthens Rare-Disease Portfolio "
BioCryst Strengthens Rare-Disease Portfolio with USD 700 Million Acquisition of Astria
Under the terms of the agreement, Astria shareholders will receive USD 8.55 per share in cash along with 0.59 BioCryst shares for each Astria share, representing a premium of about fifty-four percent over Astria’s previous closing price.
BioCryst Strengthens Rare-Disease Portfolio | 15/10/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members